NASDAQ:AKBA

Akebia Therapeutics Competitors

$2.96
-0.10 (-3.27 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.89
Now: $2.96
$3.03
50-Day Range
$2.98
MA: $3.34
$3.72
52-Week Range
$2.09
Now: $2.96
$13.71
Volume4.01 million shs
Average Volume6.27 million shs
Market Capitalization$454.37 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11

Competitors

Akebia Therapeutics (NASDAQ:AKBA) Vs. MORF, PAND, FPRX, CYTK, AMRX, and IRWD

Should you be buying AKBA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Akebia Therapeutics, including Morphic (MORF), Pandion Therapeutics (PAND), Five Prime Therapeutics (FPRX), Cytokinetics (CYTK), Amneal Pharmaceuticals (AMRX), and Ironwood Pharmaceuticals (IRWD).

Morphic (NASDAQ:MORF) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Insider and Institutional Ownership

61.5% of Morphic shares are held by institutional investors. Comparatively, 69.0% of Akebia Therapeutics shares are held by institutional investors. 39.5% of Morphic shares are held by company insiders. Comparatively, 2.6% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Morphic and Akebia Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Morphic$16.98 million105.26$-43,330,000.00($2.69)-20.48
Akebia Therapeutics$335 million1.36$-279,660,000.00($1.63)-1.82

Morphic has higher earnings, but lower revenue than Akebia Therapeutics. Morphic is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Morphic has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings for Morphic and Akebia Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Morphic00203.00
Akebia Therapeutics12502.50

Morphic presently has a consensus target price of $63.3333, indicating a potential upside of 14.98%. Akebia Therapeutics has a consensus target price of $9.6250, indicating a potential upside of 225.17%. Given Akebia Therapeutics' higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Morphic.

Profitability

This table compares Morphic and Akebia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MorphicN/A-36.62%-20.69%
Akebia Therapeutics-126.86%-68.51%-34.01%

Pandion Therapeutics (NASDAQ:PAND) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, institutional ownership and valuation.

Valuation and Earnings

This table compares Pandion Therapeutics and Akebia Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pandion Therapeutics$970,000.001,827.25$-21,880,000.00N/AN/A
Akebia Therapeutics$335 million1.36$-279,660,000.00($1.63)-1.82

Pandion Therapeutics has higher earnings, but lower revenue than Akebia Therapeutics.

Insider and Institutional Ownership

35.7% of Pandion Therapeutics shares are held by institutional investors. Comparatively, 69.0% of Akebia Therapeutics shares are held by institutional investors. 2.6% of Akebia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings for Pandion Therapeutics and Akebia Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pandion Therapeutics02202.50
Akebia Therapeutics12502.50

Pandion Therapeutics presently has a consensus target price of $44.25, indicating a potential downside of 26.31%. Akebia Therapeutics has a consensus target price of $9.6250, indicating a potential upside of 225.17%. Given Akebia Therapeutics' higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Pandion Therapeutics.

Profitability

This table compares Pandion Therapeutics and Akebia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pandion TherapeuticsN/AN/AN/A
Akebia Therapeutics-126.86%-68.51%-34.01%

Five Prime Therapeutics (NASDAQ:FPRX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk and Volatility

Five Prime Therapeutics has a beta of 4.4, suggesting that its stock price is 340% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Valuation & Earnings

This table compares Five Prime Therapeutics and Akebia Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Five Prime Therapeutics$14.87 million119.01$-137,200,000.00($3.92)-9.69
Akebia Therapeutics$335 million1.36$-279,660,000.00($1.63)-1.82

Five Prime Therapeutics has higher earnings, but lower revenue than Akebia Therapeutics. Five Prime Therapeutics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

67.3% of Five Prime Therapeutics shares are owned by institutional investors. Comparatively, 69.0% of Akebia Therapeutics shares are owned by institutional investors. 6.4% of Five Prime Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Five Prime Therapeutics and Akebia Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Five Prime Therapeutics06202.25
Akebia Therapeutics12502.50

Five Prime Therapeutics currently has a consensus price target of $30.7143, indicating a potential downside of 19.17%. Akebia Therapeutics has a consensus price target of $9.6250, indicating a potential upside of 225.17%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Five Prime Therapeutics.

Profitability

This table compares Five Prime Therapeutics and Akebia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Five Prime Therapeutics-554.71%-75.84%-49.08%
Akebia Therapeutics-126.86%-68.51%-34.01%

Summary

Akebia Therapeutics beats Five Prime Therapeutics on 10 of the 14 factors compared between the two stocks.

Cytokinetics (NASDAQ:CYTK) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk and Volatility

Cytokinetics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Valuation & Earnings

This table compares Cytokinetics and Akebia Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$26.87 million65.76$-121,690,000.00($2.11)-11.71
Akebia Therapeutics$335 million1.36$-279,660,000.00($1.63)-1.82

Cytokinetics has higher earnings, but lower revenue than Akebia Therapeutics. Cytokinetics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

97.1% of Cytokinetics shares are owned by institutional investors. Comparatively, 69.0% of Akebia Therapeutics shares are owned by institutional investors. 6.4% of Cytokinetics shares are owned by company insiders. Comparatively, 2.6% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Cytokinetics and Akebia Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cytokinetics011002.91
Akebia Therapeutics12502.50

Cytokinetics currently has a consensus price target of $33.6364, indicating a potential upside of 36.18%. Akebia Therapeutics has a consensus price target of $9.6250, indicating a potential upside of 225.17%. Given Akebia Therapeutics' higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Cytokinetics.

Profitability

This table compares Cytokinetics and Akebia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cytokinetics-209.88%-3,065.14%-36.39%
Akebia Therapeutics-126.86%-68.51%-34.01%

Summary

Akebia Therapeutics beats Cytokinetics on 8 of the 14 factors compared between the two stocks.

Amneal Pharmaceuticals (NYSE:AMRX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk and Volatility

Amneal Pharmaceuticals has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Valuation & Earnings

This table compares Amneal Pharmaceuticals and Akebia Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amneal Pharmaceuticals$1.63 billion1.09$-361,920,000.00$0.2721.81
Akebia Therapeutics$335 million1.36$-279,660,000.00($1.63)-1.82

Akebia Therapeutics has lower revenue, but higher earnings than Amneal Pharmaceuticals. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.0% of Akebia Therapeutics shares are owned by institutional investors. 26.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Amneal Pharmaceuticals and Akebia Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amneal Pharmaceuticals01502.83
Akebia Therapeutics12502.50

Amneal Pharmaceuticals currently has a consensus price target of $7.00, indicating a potential upside of 18.85%. Akebia Therapeutics has a consensus price target of $9.6250, indicating a potential upside of 225.17%. Given Akebia Therapeutics' higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Amneal Pharmaceuticals.

Profitability

This table compares Amneal Pharmaceuticals and Akebia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amneal Pharmaceuticals3.30%42.02%3.82%
Akebia Therapeutics-126.86%-68.51%-34.01%

Summary

Amneal Pharmaceuticals beats Akebia Therapeutics on 8 of the 13 factors compared between the two stocks.

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Risk and Volatility

Ironwood Pharmaceuticals has a beta of 1.46, suggesting that its stock price is 46% more volatile than the S&P 500. Comparatively, Akebia Therapeutics has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Ironwood Pharmaceuticals and Akebia Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Ironwood Pharmaceuticals04102.20
Akebia Therapeutics12502.50

Ironwood Pharmaceuticals currently has a consensus price target of $11.40, indicating a potential upside of 7.45%. Akebia Therapeutics has a consensus price target of $9.6250, indicating a potential upside of 225.17%. Given Akebia Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Ironwood Pharmaceuticals.

Insider & Institutional Ownership

69.0% of Akebia Therapeutics shares are owned by institutional investors. 2.4% of Ironwood Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Ironwood Pharmaceuticals and Akebia Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Ironwood Pharmaceuticals27.77%-240.80%27.05%
Akebia Therapeutics-126.86%-68.51%-34.01%

Valuation & Earnings

This table compares Ironwood Pharmaceuticals and Akebia Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ironwood Pharmaceuticals$428.41 million3.99$21.50 million$0.5519.29
Akebia Therapeutics$335 million1.36$-279,660,000.00($1.63)-1.82

Ironwood Pharmaceuticals has higher revenue and earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.


Akebia Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MORF
Morphic
1.3$55.08-0.6%$1.79 billion$16.98 million-35.31Insider Selling
Decrease in Short Interest
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$38.00-0.0%$1.77 billion$14.87 million-14.18Increase in Short Interest
News Coverage
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.70-0.7%$1.77 billion$26.87 million-12.93Insider Selling
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.8$5.89-0.2%$1.77 billion$1.63 billion14.37Analyst Report
Decrease in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.61-2.2%$1.71 billion$428.41 million15.38News Coverage
Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.70-0.5%$1.68 billion$392.76 million13.15Analyst Upgrade
Analyst Revision
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.06-1.0%$1.64 billionN/A-6.43Increase in Short Interest
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$17.87-0.8%$1.63 billion$145.97 million-7.23
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.29-1.4%$1.60 billion$2.34 million-9.87
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.15-0.5%$1.60 billionN/A0.00Analyst Revision
News Coverage
Generation Bio logo
GBIO
Generation Bio
1.8$28.30-2.8%$1.60 billionN/A0.00Insider Selling
Increase in Short Interest
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.35-2.0%$1.57 billion$320,000.00-8.40News Coverage
uniQure logo
QURE
uniQure
1.7$34.07-4.1%$1.53 billion$7.28 million-9.04Insider Selling
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$24.95-4.0%$1.51 billion$175.34 million-14.68Analyst Downgrade
Analyst Revision
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.52-2.4%$1.50 billion$82.27 million-18.34Gap Down
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$32.24-5.2%$1.50 billionN/A0.00Analyst Upgrade
News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$41.84-3.6%$1.47 billionN/A0.00
OLMA
Olema Pharmaceuticals
1.6$36.14-2.1%$1.45 billionN/A0.00Increase in Short Interest
News Coverage
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$32.37-0.9%$1.45 billionN/A0.00Insider Selling
Increase in Short Interest
Endo International logo
ENDP
Endo International
1.3$6.26-3.4%$1.44 billion$2.91 billion-9.21
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$28.51-0.7%$1.42 billion$19.89 million-13.45Analyst Report
News Coverage
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$21.71-1.0%$1.42 billion$73.41 million-4.59
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.56-0.8%$1.41 billion$6.20 million-14.28News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$30.38-0.7%$1.40 billion$29.54 million-8.06Unusual Options Activity
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$34.85-0.7%$1.39 billionN/A-145.21
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$26.68-1.3%$1.38 billion$4.23 million-19.76Increase in Short Interest
Gap Down
ATBPD
Antibe Therapeutics
0.1$3.57-0.3%$1.38 billion$7.51 million-5.95Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$27.52-4.2%$1.38 billionN/A-2.98Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$56.67-12.0%$1.32 billionN/A0.00Increase in Short Interest
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$34.35-0.9%$1.26 billionN/A0.00Analyst Upgrade
News Coverage
Shattuck Labs logo
STTK
Shattuck Labs
1.5$30.01-5.6%$1.25 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.68-1.1%$1.25 billionN/A0.00
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.99-1.2%$1.24 billion$35.22 million-8.02News Coverage
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.89-1.6%$1.21 billion$4.23 million-8.88Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$21.56-0.7%$1.21 billionN/A0.00Insider Selling
Innoviva logo
INVA
Innoviva
1.4$11.90-0.1%$1.21 billion$261.02 million6.07
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.16-1.7%$1.17 billion$59.70 million-191.60Gap Down
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.55-0.3%$1.16 billion$230,000.00-12.35
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$37.01-0.0%$1.16 billionN/A-2.65
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$16.65-3.7%$1.15 billion$42.12 million-12.33Unusual Options Activity
Gap Down
NKTX
Nkarta
1.8$34.87-5.2%$1.14 billionN/A0.00Increase in Short Interest
News Coverage
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.22-4.1%$1.14 billionN/A-8.83Insider Selling
Increase in Short Interest
Gap Down
Omeros logo
OMER
Omeros
1.4$18.37-0.2%$1.14 billion$111.81 million-7.72News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.91-6.5%$1.13 billionN/A-17.17
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$29.93-2.4%$1.07 billion$57.05 million0.00Insider Selling
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.29-4.5%$1.07 billionN/A-8.23Unusual Options Activity
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$15.63-5.2%$1.07 billionN/A-6.59Gap Down
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$40.33-2.0%$1.06 billion$20.79 million-13.91News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.00-3.5%$1.06 billion$3.65 million-2.00Analyst Upgrade
News Coverage
Gap Down
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.